No Data
No Data
TD Cowen Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $35
TD Cowen Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Express News | ACADIA Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $19 to $39
Shareholders in ACADIA Pharmaceuticals (NASDAQ:ACAD) Have Lost 60%, as Stock Drops 4.0% This Past Week